AstraZeneca linked to inflammation of the spinal cord by European Medicines Agency

Please share this story - thanks

AstraZeneca has been associated with cases of transverse myelitis – inflammation of the spinal cord – by the EMA (European Medicines Agency). The EMA safety update is here (PDF) which also includes details about the Janssen jab.

In a report, published Thursday 27 January, the Mail states that as of Wednesday, January 26 2022, transverse myelitis has officially been added to the “warnings and precautions [of] neurological events” section given to healthcare professionals.

The UK’s medicines agency – the MHRA – says cases of the known side-effect are “extremely rare” but the reaction can lead to:

  • Muscle weakness
  • Localised or radiating back pain
  • Bladder issues
  • Bowel symptoms and changes in sensations

According to the Mail report, the neurological disorder often damages the insulating material covering nerve cell fibres (myelin), meaning that messages the spinal cord sends throughout the body are disturbed.

The EMA warning also says an assessment of whether vaccination with AstraZeneca or Janssen can cause capillary leak syndrome (leakage of fluid from blood vessels) is ongoing.

Full story here.

See also this CNN report from September 2020 here which states: CNN has obtained an internal safety report by pharmaceutical giant AstraZeneca that sheds light on the neurological condition suffered by one of the participants in its coronavirus vaccine clinical trial.

The report details how the study volunteer, a previously healthy 37-year-old woman, “experienced confirmed transverse myelitis” after receiving her second dose of the vaccine, and was hospitalized on September 5.

Please share this story - thanks